Scott D Berkowitz

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 35

Top Venues

Journal of the American Heart Association

Circulation

Journal of cardiovascular development and disease

Journal of thrombosis and thrombolysis

Bayer U.S., LLC

University of Delaware (BSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Bayer U.S., LLC

United States

Vice President & Group Head, Clinical Development Thrombsis :: Research & Development

AstraZeneca Pharmaceuticals LP

United States

Senior Medical Director :: Clinical Research

Duke Clinical Research Institute

United States

Assistant/Associate Professor

Duke University Medical Center

United States

Assistant/Associate Professor of Medicine & Pathology :: Medicine & Pathology

Scripps Immunology Reference Lab/Scripps Research Institute

United States

Coagulation Consultant

Scripps Clinic Medical Group

United States

Staff Physician, & Consultant in Coagulation Dept of Pathology :: Medicine/Division of Hematology/Oncology

Southern California Permanente Medical Group

United States

Staff Physician - Hematology/Oncology :: Medicine/Hematology & Medical Oncology

Education History

University of Delaware

United States

BSC

Publications

Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association (2024)
Josephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, Guenter Breithardt, Jonathan L Halperin, Graeme J Hankey, Richard C Becker, Christopher C Nessel, Scott D Berkowitz, Keith A A Fox, Daniel E Singer, Shaun G Goodman, Manesh R Patel, Jonathan P Piccini
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal of the American Heart Association 13 (11) (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Josephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, Guenter Breithardt, Jonathan L Halperin, Graeme J Hankey, Richard C Becker, Christopher C Nessel, Scott D Berkowitz, Keith A A Fox, Daniel E Singer, Shaun G Goodman, Manesh R Patel, Jonathan P Piccini
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal of the American Heart Association 13 (11) (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Josephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, Guenter Breithardt, Jonathan L Halperin, Graeme J Hankey, Richard C Becker, Christopher C Nessel, Scott D Berkowitz, Keith A A Fox, Daniel E Singer, Shaun G Goodman, Manesh R Patel, Jonathan P Piccini
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal of the American Heart Association 13 (11) (2024)
Josephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, Guenter Breithardt, Jonathan L Halperin, Graeme J Hankey, Richard C Becker, Christopher C Nessel, Scott D Berkowitz, Keith A A Fox, Daniel E Singer, Shaun G Goodman, Manesh R Patel, Jonathan P Piccini
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal of the American Heart Association 13 (11) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Justin T Morrison, Mario Enrico Canonico, Sonia S Anand, Manesh R Patel, Eike Sebastian Debus, Mark R Nehler, Connie N Hess, Judith Hsia, Warren H Capell, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation 149 (19) (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Josephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, Guenter Breithardt, Jonathan L Halperin, Graeme J Hankey, Richard C Becker, Christopher C Nessel, Scott D Berkowitz, Keith A A Fox, Daniel E Singer, Shaun G Goodman, Manesh R Patel, Jonathan P Piccini
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal of the American Heart Association (2024)
Shea E Hogan, Eike Sebastian Debus, Mark R Nehler, Manesh R Patel, Sonia S Anand, Eva Muehlhofer, Lloyd P Haskell, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation 149 (8) (2024)
Josephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, Guenter Breithardt, Jonathan L Halperin, Graeme J Hankey, Richard C Becker, Christopher C Nessel, Scott D Berkowitz, Keith A A Fox, Daniel E Singer, Shaun G Goodman, Manesh R Patel, Jonathan P Piccini
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis. Journal of the American Heart Association 13 (11) (2024)
Jennifer A Rymer, Sonia S Anand, Eike Sebastian Debus, Lloyd P Haskell, Connie N Hess, W Schuyler Jones, Eva Muehlhofer, Scott D Berkowitz, Rupert M Bauersachs, Marc P Bonaca, Manesh R Patel
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation (2023)
Mario Enrico Canonico, Raffaele Piccolo, Marisa Avvedimento, Attilio Leone, Salvatore Esposito, Anna Franzone, Giuseppe Giugliano, Giuseppe Gargiulo, Connie N Hess, Scott D Berkowitz, Judith Hsia, Plinio Cirillo, Giovanni Esposito, Marc P Bonaca
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of cardiovascular development and disease 10 (4) (2023)
Mario Enrico Canonico, Raffaele Piccolo, Marisa Avvedimento, Attilio Leone, Salvatore Esposito, Anna Franzone, Giuseppe Giugliano, Giuseppe Gargiulo, Connie N Hess, Scott D Berkowitz, Judith Hsia, Plinio Cirillo, Giovanni Esposito, Marc P Bonaca
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of cardiovascular development and disease 10 (4) (2023)
Mario Enrico Canonico, Raffaele Piccolo, Marisa Avvedimento, Attilio Leone, Salvatore Esposito, Anna Franzone, Giuseppe Giugliano, Giuseppe Gargiulo, Connie N Hess, Scott D Berkowitz, Judith Hsia, Plinio Cirillo, Giovanni Esposito, Marc P Bonaca
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of cardiovascular development and disease 10 (4) (2023)
Mario Enrico Canonico, Raffaele Piccolo, Marisa Avvedimento, Attilio Leone, Salvatore Esposito, Anna Franzone, Giuseppe Giugliano, Giuseppe Gargiulo, Connie N Hess, Scott D Berkowitz, Judith Hsia, Plinio Cirillo, Giovanni Esposito, Marc P Bonaca
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of cardiovascular development and disease 10 (4) (2023)
Connie N Hess, Iris Baumgartner, Sonia S Anand, Mark R Nehler, Manesh R Patel, Eike Sebastian Debus, Michael Szarek, Warren Capell, Eva Muehlhofer, Scott D Berkowitz, Lloyd P Haskell, Rupert M Bauersachs, Marc P Bonaca, Judith Hsia
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association 11 (12) (2022)
Shea E Hogan, Mark R Nehler, Sonia S Anand, Manesh R Patel, Sebastian Debus, Matthew T Jackson, Cullen Buchanan, R Wilson King, Connie Hess, Eva Muehlhofer, Lloyd P Haskell, Rupert M Bauersachs, Scott D Berkowitz, Judith Hsia, Marc P Bonaca
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vascular medicine (London, England) 27 (4) (2022)
Scott D Berkowitz, Rupert M Bauersachs, Michael Szarek, Mark R Nehler, Eike Sebastian Debus, Manesh R Patel, Sonia S Anand, Warren H Capell, Connie N Hess, Judith Hsia, Nicholas J Leeper, David De Padua Brasil, Lajos Mátyás, Rafael Diaz, Marianne Brodmann, Eva Muehlhofer, Lloyd P Haskell, Marc P Bonaca
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of thrombosis and haemostasis : JTH 20 (5) (2022)
Sonia S Anand, Will Hiatt, Leanne Dyal, Rupert M Bauersachs, Scott D Berkowitz, Kelley R H Branch, Sebastian Debus, Keith A A Fox, Yan Liang, Eva Muehlhofer, Mark R Nehler, Lloyd P Haskell, Manesh Patel, Michael Szarek, Salim Yusuf, John William Eikelboom, Marc P Bonaca
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European journal of preventive cardiology (2021)
Isabel Reinecke, Alexander Solms, Stefan Willmann, Theodore E Spiro, Gary Peters, Jeffrey I Weitz, Wolfgang Mueck, Dirk Garmann, Stephan Schmidt, Liping Zhang, Keith A A Fox, Scott D Berkowitz
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. Journal of thrombosis and thrombolysis 50 (1) (2021)
Mori J Krantz, Sebastian E Debus, Judith Hsia, Manesh R Patel, Sonia S Anand, Mark R Nehler, Connie N Hess, Warren H Capell, Taylor Bracken, Michael Szarek, Lajos Mátyás, Dainis K Krievins, Patrice Nault, Stefan Stefanov, Lloyd P Haskell, Scott D Berkowitz, Eva Muehlhofer, William R Hiatt, Rupert M Bauersachs, Marc P Bonaca
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. European heart journal 42 (39) (2021)
Anthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, Daniel E Singer, Guenter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, Scott D Berkowitz, Keith A A Fox, Robert M Califf, Manesh R Patel
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. Journal of the American Heart Association 10 (19) (2021)
Gilles R Dagenais, Leanne Dyal, Jacqueline J Bosch, Darryl P Leong, Victor Aboyans, Scott D Berkowitz, Deepak L Bhatt, Stuart J Connolly, Keith A A Fox, Eva Muehlhofer, Jeffrey L Probstfield, Petr Widimsky, Bernhard R Winkelmann, Salim Yusuf, John W Eikelboom
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Heart (British Cardiac Society) 107 (14) (2021)
Mukul Sharma, Eric Edward Smith, Lesly A Pearce, Ashkan Shoamanesh, Kanjana S Perera, Shelagh B Coutts, Dorte Damgaard, Sebastián Francisco Ameriso, Joung-Ho Rha, Boris Modrau, Byung-Woo Yoon, Marina Romano, Steven R Messe, Jessica Barlinn, Johann Lambeck, Feryal Saad, Scott D Berkowitz, Hardi Mundl, Stuart J Connolly, Robert G Hart, null null
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. Stroke (2021)
Alexander Solms, Stefan Willmann, Isabel Reinecke, Theodore E Spiro, Gary Peters, Jeffrey I Weitz, Wolfgang Mueck, Dirk Garmann, Stephan Schmidt, Liping Zhang, Keith A A Fox, Scott D Berkowitz
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of thrombosis and thrombolysis 50 (1) (2021)
Connie N Hess, Eike Sebastian Debus, Mark R Nehler, Sonia S Anand, Manesh R Patel, Michael Szarek, Warren H Capell, Judith Hsia, Joshua A Beckman, Marianne Brodmann, Rafael Diaz, Peter Habertheuer, Nicholas J Leeper, Richard J Powell, Henrik Sillesen, Eva Muehlhofer, Scott D Berkowitz, Lloyd P Haskell, Rupert M Bauersachs, Marc P Bonaca
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation 144 (23) (2021)
Guy Aaron Young, Anthonie W A Lensing, Paul Monagle, Christoph Male, Kirstin Thelen, Stefan Willmann, Joseph S Palumbo, Riten Kumar, Ildar Nurmeev, Kerry Hege, Fanny Bajolle, Philip Connor, Hélène L Hooimeijer, Marcela Torres, Anthony K C Chan, Gili Kenet, Susanne Holzhauer, Amparo Santamaría, Pascal Amedro, Jan Beyer-Westendorf, Ida Martinelli, M Patricia Massicotte, William T Smith, Scott D Berkowitz, Stephan Schmidt, Victoria Price, Martin H Prins, Dagmar Kubitza, null null
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. Journal of thrombosis and haemostasis : JTH 18 (7) (2020)
Liping Zhang, Xiaoyu Yan, Partha Nandy, Stefan Willmann, Keith A A Fox, Scott D Berkowitz, Amarnath Sharma, Anne Hermanowski-Vosatka, Stephan Schmidt, Jeffrey I Weitz, Dirk Garmann, Gary Peters
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. Therapeutic advances in cardiovascular disease 13 (2019)

Scott D Berkowitz.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Scott D Berkowitz